Skip to main content
TipRanks
Go Ultimate75% OFF

Active Biotech AB (ACTI) AI Stock Analysis

0 Followers
SE:ACTI

Active Biotech AB

(Nasdaq OMX AB:ACTI)

Select Model
Rating:38Underperform
Price Target:SEK 3.50â–²(0.00% Upside)
Action:downgraded
Date:11/13/26

The overall score is severely pressured by the company's pre-revenue status and ongoing cash burn, which represent existential financial risks. The stock's weak technical position, trading below all major moving averages, reinforces the negative outlook. A debt-free balance sheet offers some stability, but it is insufficient to offset the fundamental lack of commercial viability and the absence of any positive valuation or earnings catalysts.

Positive Factors
Low LeverageVery limited debt reduces fixed financial obligations and leaves the company less exposed to interest costs or refinancing pressure. This provides some balance-sheet flexibility while Active Biotech advances its development programs, although operating losses still require careful funding management.
Negative Factors
No Reported RevenueThe absence of reported revenue means the company has not yet demonstrated commercial monetization of its development activities. This leaves financial performance dependent on future partnering, milestone, licensing, or product outcomes rather than an established recurring revenue base.

Active Biotech AB (ACTI) vs. iShares MSCI Sweden ETF (EWD)

-60%-40%-20%0%20%40%SE:ACTI-46.56%EWD+15.06%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
SEK 92.53M
Dividend Yield
―
Average Volume (3M)
56.21K
Price to Earnings (P/E)
-5.0
Beta (1Y)
0.11
Revenue Growth
―
EPS Growth
51.09%
Country
Sweden
Employees
5
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Active Biotech AB Business Overview & Revenue Model

Company Description

Active Biotech AB (publ), a biotechnology company, engages in the research, development, production, marketing, and sale of medical, chemical, and biotechnology products in Sweden. It is developing Tasquinimod, a small molecule immunomodulator, which...

How the Company Makes Money

Active Biotech AB’s ability to generate revenue is primarily linked to the monetization of its drug development pipeline rather than product sales. Typical revenue sources for a clinical-stage biotech include (1) out-licensing or partnering its drug...

Active Biotech AB Financial Statement Overview

Summary

The company is pre-revenue with zero top-line generation, which is a critical weakness. While net losses have narrowed and the balance sheet is debt-free, the sustained cash burn and rapidly declining equity base indicate a fundamentally unsustainable financial trajectory without additional capital.

Income Statement

1Very Negative

Balance Sheet

45Neutral

Cash Flow

20Very Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue000000
Gross Profit-1.60M-1.60M-1.64M-1.68M-1.49M-1.28M
EBITDA-34.80M-36.00M-38.26M-43.89M-56.67M-48.52M
Net Income-35.90M-37.30M-39.40M-45.80M-58.69M-49.88M
Balance Sheet
Total Assets41.10M70.20M43.20M44.05M51.01M56.80M
Cash, Cash Equivalents and Short-Term Investments36.30M65.10M27.40M36.22M41.80M53.13M
Total Debt01.74M3.18M4.54M6.04M986.00K
Total Liabilities12.30M14.60M11.13M13.38M16.49M10.13M
Stockholders Equity28.80M55.60M32.07M30.67M34.51M46.67M
Cash Flow
Free Cash Flow-31.40M-32.40M-40.40M-45.74M-55.09M-46.17M
Operating Cash Flow-31.40M-32.40M-40.40M-45.74M-54.85M-46.17M
Investing Cash Flow0000-245.00K0
Financing Cash Flow58.50M70.10M31.60M40.16M43.76M73.09M

Active Biotech AB Technical Analysis

Technical Analysis SentimentNegative
Last Price3.50

Price Trends

50DMA3.78Negative
100DMA4.53Negative
200DMA5.06Negative

Market Momentum

MACD-0.06Positive
RSI45.00Neutral
STOCH29.42Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ACTI, the sentiment is Negative. The current price of 3.50 is below the 20-day moving average (MA) of 3.61, below the 50-day MA of 3.78, and below the 200-day MA of 5.06, indicating a bearish trend. The MACD of -0.06 indicates Positive momentum. The RSI at 45.00 is Neutral, neither overbought nor oversold. The STOCH value of 29.42 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:ACTI.

Active Biotech AB Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

SE:ACTI against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
SE:CANTASE:CANTA83OutperformSEK 386.26M2.0163.09%―――
SE:HNSASE:HNSA60NeutralSEK 5.04B-6.27――68.88%10.63%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
SE:ONCOSE:ONCO44NeutralSEK 763.93M-2.81――65.37%43.28%
SE:BINVSE:BINV43NeutralSEK 180.96M-0.37-128.54%―-83.67%-50.29%
SE:SYNACTSE:SYNACT43NeutralSEK 804.98M-7.66-60.58%――14.35%
SE:ACTISE:ACTI38UnderperformSEK 92.53M-5.01-85.07%――51.09%

* Healthcare Sector Average

Performance Comparison

-50%0%50%SE:ACTISE:HNSASE:BINVSE:ONCOSE:SYNACTSE:CANTADec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
SE:ACTI and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
SE:ACTIActive Biotech AB3.50-2.97-45.94%
SE:HNSAHansa Biopharma48.1821.0277.39%
SE:BINVBioInvent International AB2.94-28.31-90.59%
SE:ONCOOncopeptides AB1.73-3.10-64.14%
SE:SYNACTSynAct Pharma AB13.58-7.27-34.87%
SE:CANTACantargia AB1.31-1.86-58.64%

Active Biotech AB Corporate Events

Active Biotech Clears First Safety Cohort in Tasquinimod Myelofibrosis Trial

Oct 13, 2026

Active Biotech has reported that the first cohort of three patients treated under an amended protocol in the European Phase Ib/II HOVON 172 MF study of tasquinimod in myelofibrosis has completed a six-week safety evaluation. One serious adverse event...

Active Biotech Wins Japanese Patent for Laquinimod Eye Treatment, Bolstering Global IP Strategy

Sep 30, 2026

Active Biotech has secured a key patent in Japan for an ophthalmic eye-drop formulation of its clinical candidate laquinimod, designed to deliver the drug to the posterior parts of the eye for treating severe inflammatory conditions such as non-infec...

Active Biotech Deepens U.S. Ties to Advance Tasquinimod in Myelofibrosis

Aug 18, 2026

Active Biotech has expanded its U.S. collaboration by signing a new agreement with the Icahn School of Medicine at Mount Sinai, part of the Myeloproliferative Neoplasms Research Consortium, to support development of its drug candidate tasquinimod for...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 13, 2026